Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

September 27, 2021

The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls

Hae Lim Lee, Sung Won Lee

Clin Mol Hepatol. 2022;28(2):121-134.

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective interventional procedure to relieve portal hypertension, which is a main mechanism for the development of complications of liver cirrhosis (LC), such as...

Review

October 22, 2021

Approaches to quantifying hepatitis B virus covalently closed circular DNA

Henrik Zhang, Thomas Tu

Clin Mol Hepatol. 2022;28(2):135-149.

Chronic hepatitis B is a major cause of liver disease worldwide and is currently incurable. Hepatitis B virus (HBV) covalently closed circular (ccc) DNA is a key form of the...

Review

November 10, 2021

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, et al.

Clin Mol Hepatol. 2022;28(2):150-163.

Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight...

Review

December 27, 2021

Cost-effectiveness of chronic hepatitis C screening and treatment

Hye Won Lee, Hankil Lee, Beom Kyung Kim, et al.

Clin Mol Hepatol. 2022;28(2):164-173.

Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence...

Original Article

November 28, 2021

Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients

Wen-Yue Liu, Xiaofang Zhang, Gang Li, et al.

Clin Mol Hepatol. 2022;28(2):183-195.

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL)...

Original Article

January 13, 2022

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee, Taeyun Kim, Hyun Yang, et al.

Clin Mol Hepatol. 2022;28(2):196-206.

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) has become a major concern in Korea since its emergence as a dominant cause of chronic liver disease. However, no study has explored its...

Original Article

November 24, 2021

Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma

Jungnam Lee, Young-Joo Jin, Seung Kak Shin, et al.

Clin Mol Hepatol. 2022;28(2):207-218.

Background/Aims: We compared the post-treatment overall survival (OS) and recurrence-free survival (RFS) between patients with Child-Turcotte-Pugh (CTP) class-A and single small (≤3 cm) hepatocellular carcinoma (HCC) treated by surgical resection...

Original Article

July 20, 2021

Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis

Ji Won Han, Da In Kim, Hee Chul Nam, et al.

Clin Mol Hepatol. 2022;28(2):219-231.

Background/Aims: Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear. Methods: Sprague-Dawley rats were treated with thioacetamide (TAA) or...

Original Article

January 5, 2022

Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats

Ki Tae Yoon, Hongqun Liu, Jing Zhang, et al.

Clin Mol Hepatol. 2022;28(2):232-241.

Background/Aims: Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac...

Original Article

February 7, 2022

Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area

Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, et al.

Clin Mol Hepatol. 2022;28(2):242-253.

Background/Aims: Primary liver cancer is one of the leading causes of cancer mortality worldwide. However, the causes of death have not been studied in detail in patients with liver cancer. Methods:...

Original Article

December 28, 2021

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, et al.

Clin Mol Hepatol. 2022;28(2):254-264.

Background/Aims: Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis...

Current Issue: Volume 28(2); Apr 2022

This archive contains links to the full-text of all issues of Clin Mol Hepatol.

Current issue

Volume 28(2); April

All issues

Vol. 28
2022

v.28(1)
Jan 2022

v.28(2)
Apr 2022

Vol. 27
2021

v.27(1)
Jan 2021

v.27(2)
Apr 2021

v.27(3)
Jul 2021

v.27(4)
Oct 2021

Vol. 26
2020

v.26(1)
Jan 2020

v.26(2)
Apr 2020

v.26(3)
Jul 2020

v.26(4)
Oct 2020

Vol. 25
2019

v.25(1)
Mar 2019

v.25(2)
Jun 2019

v.25(3)
Sep 2019

v.25(4)
Dec 2019

Vol. 24
2018

v.24(1)
Mar 2018

v.24(2)
Jun 2018

v.24(3)
Sep 2018

v.24(4)
Dec 2018

Vol. 23
2017

v.23(1)
Mar 2017

v.23(2)
Jun 2017

v.23(3)
Sep 2017

v.23(4)
Dec 2017

Vol. 22
2016

v.22(1)
Mar 2016

v.22(2)
Jun 2016

v.22(3)
Sep 2016

v.22(4)
Dec 2016

Vol. 21
2015

v.21(1)
Mar 2015

v.21(2)
Jun 2015

v.21(3)
Sep 2015

v.21(4)
Dec 2015

Vol. 20
2014

v.20(1)
Mar 2014

v.20(2)
Jun 2014

v.20(3)
Sep 2014

v.20(4)
Dec 2014

Vol. 19
2013

v.19(1)
Mar 2013

v.19(2)
Jun 2013

v.19(3)
Sep 2013

v.19(4)
Dec 2013

The Korean Journal of Hepatology1995 (Vol.1 No.1) to 2012 (Vol.18 No.1)

Vol. 18
2012

v.18(1)
Mar 2012

v.18(2)
Jun 2012

v.18(3)
Sep 2012

v.18(4)
Dec 2012

Vol. 17
2011

v.17(1)
Mar 2011

v.17(2)
Jun 2011

v.17(3)
Sep 2011

v.17(4)
Dec 2011

Vol. 16
2010

v.16(1)
Mar 2010

v.16(2)
Jun 2010

v.16(3)
Sep 2010

v.16(4)
Dec 2010

Vol. 15
2009

v.15(1)
Mar 2009

v.15(2)
Jun 2009

v.15(3)
Sep 2009

v.15(4)
Dec 2009

v.15(60)
Dec 2009

Vol. 14
2008

v.14(1)
Mar 2008

v.14(2)
Jun 2008

v.14(3)
Sep 2008

v.14(4)
Dec 2008

Vol. 13
2007

v.13(1)
Mar 2007

v.13(2)
Jun 2007

v.13(3)
Sep 2007

v.13(4)
Dec 2007

Vol. 12
2006

v.12(1)
Mar 2006

v.12(2)
Jun 2006

v.12(3)
Sep 2006

v.12(4)
Dec 2006

Vol. 11
2005

v.11(1)
Mar 2005

v.11(2)
Jun 2005

v.11(3)
Sep 2005

v.11(4)
Dec 2005

Vol. 10
2004

v.10(1)
Mar 2004

v.10(2)
Jun 2004

v.10(3)
Sep 2004

v.10(4)
Dec 2004

Vol. 9
2003

v.9(1)
Mar 2003

v.9(2)
Jun 2003

v.9(3)
Sep 2003

v.9(4)
Dec 2003

Vol. 8
2002

v.8(1)
Mar 2002

v.8(2)
Jun 2002

v.8(3)
Sep 2002

v.8(4)
Dec 2002

Vol. 7
2001

v.7(1)
Mar 2001

v.7(2)
Jun 2001

v.7(3)
Sep 2001

v.7(4)
Dec 2001

Vol. 6
2000

v.6(1)
Mar 2000

v.6(2)
Jun 2000

v.6(3)
Sep 2000

v.6(4)
Dec 2000

Vol. 5
1999

v.5(1)
Mar 1999

v.5(2)
Jun 1999

v.5(3)
Sep 1999

v.5(4)
Dec 1999

Vol. 4
1998

v.4(1)
Mar 1998

v.4(2)
Jun 1998

v.4(3)
Sep 1998

v.4(4)
Dec 1998

Vol. 3
1997

v.3(1)
Mar 1997

v.3(2)
Jun 1997

v.3(3)
Sep 1997

v.3(4)
Dec 1997

Vol. 2
1996

v.2(1)
Jun 1996

v.2(2)
Dec 1996

Vol. 1
1995

v.1(1)
Jun 1995

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

First decision

09 Days

Publication after acceptance

04 Days

*Last 12 months

Viewed By 8477	Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Viewed By 3933	Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Viewed By 3726	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Viewed By 2747	KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications
Viewed By 2236	Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

Cited By 43	Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
Cited By 32	Application of transient elastography in nonalcoholic fatty liver disease
Cited By 30	Novel biomarkers for the management of chronic hepatitis B
Cited By 29	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Cited By 28	Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy